SIDMAP Provides Metabolic Phenotyping Services to Researchers at Harvard Medical School's Joslin Diabetes Center and the University of Utah
Posted on: Tuesday, 16 August 2005, 18:00 CDT
SIDMAP, a Los Angeles-based company focused on metabolic phenotyping services for the biotech and pharmaceutical industry, today announced that the company signed agreements with investigators and researchers at Harvard Medical School's Joslin Diabetes Center and the University of Utah to use its patent-pending stable isotope-based metabolic phenotyping services.
Mary-Elizabeth Patti, M.D., of the Joslin Diabetes Center at Harvard Medical School, engaged SIDMAP to conduct a series of profiles to determine the metabolic perturbations of a diabetes model currently under investigation. "The early information provided by SIDMAP has been extremely revealing. The results were provided promptly and I expect to continue working with Dr. Boros and his team in the future," Dr. Patti said.
Don McClain, Ph.D., of the University of Utah, is using SIDMAP's metabolic phenotyping services to evaluate an in vivo model for type II diabetes. "The work Drs. Boros and Lee are doing is extremely exciting and we are expecting some unique insights from the metabolic profiles SIDMAP is providing," said Dr. McClain.
"We are extremely pleased that these prestigious academic institutions have chosen SIDMAP as their metabolic solutions provider," said David Manheim, SIDMAP's Vice President of Operations and General Counsel. "We continue to work with pharmaceutical and biotech companies as well as academic institutions which have embraced our technology as a useful tool to enhance their research and drug development efforts. Our pipeline is robust and should continue to grow as more people learn about the dynamic biochemical information we provide."
Financial terms of the agreements were not disclosed.
About SIDMAP
SIDMAP provides metabolic phenotyping services to pharmaceutical, biotech and research organizations seeking to enhance the drug discovery and development process, and develop further insight into disease states. SIDMAP's unique, patent-pending tracer technology, exclusively licensed from Los Angeles BioMedical Research Institute at Harbor U.C.L.A Medical Center, measures metabolic pathway flux to gain unique insight into cell function. A SIDMAP profile provides clients with an accurate metabolic analysis of a compound's biological impact using both in vitro and in vivo systems, before a company spends millions on development and clinical trials. SIDMAP is headquartered in Los Angeles, Calif.
Source: Business Wire
Related Articles
- Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting
- Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD)
- Paperless Self-Service Check-In a Success at Medical Center of Central Georgia
- Sysmex America Awarded Contract to Service Veterans Affairs Medical Centers in Midwest States
- Language Access Network to Provide Telephonic Interpretation Service to OSU Medical Center
- Overlake Hospital Medical Center to Continue Its Relationship With Premier Inc.
- Time Warner Telecom Delivers Comprehensive Voice and Data Services for Kettering Medical Center Network
- Orange County, Calif., Medical Center Withdraws From Insurance Program
- Stem Cell Research: Too Hot to Handle? Backers of a UNMC Proposal Cite Its Potential to Ease Suffering, but Regent Randy Ferlic Fears Political Heat.Medical Center Research Plan
 |
 |
User Comments (0)
RSS Feeds